GleamWall
中文EN

SNGX SOLIGENIX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—

Returns

ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$119,371
Cost of revenue—$119,371
Gross profit—$0
R&D expense$7.49M$5.22M
SG&A expense$4.36M$4.22M
Operating income-$11.85M-$9.44M
Pretax income-$11.59M-$8.68M
Income tax-$506,615-$409,114
Net income-$11.08M-$8.27M
EPS (basic)-2.14-4.98
EPS (diluted)-2.14-4.98
Weighted avg. shares (diluted)5.19M1.66M
Balance sheet
Cash & equivalents$7.94M$7.82M
Current assets$8.85M$8.83M
PP&E, net$8,772$6,113
Total assets$9.24M$8.97M
Current liabilities$3.70M$4.85M
Long-term debt—$0
Total debt—$0
Total liabilities$3.94M$4.85M
Shareholders' equity$5.29M$4.12M
Net debt—-$7.82M
Shares outstanding10.09M2.51M
Cash flow statement
Operating cash flow-$10.27M-$8.40M
Capital expenditure$5,883—
Free cash flow-$10.27M—
Investing cash flow-$5,883—
Financing cash flow$10.39M$7.76M
Stock-based compensation$587,583$329,815

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.